Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial - Powles, T; Plimack, ER; Soulières, D (Lancet Oncol, 2020)
et al.